Recent Articles

Avelumab Becomes First Approved Treatment for Patients with Merkel Cell Carcinoma

| April 3, 2017 | 0 Comments

Avelumab Becomes First Approved Treatment for Patients with Merkel Cell Carcinoma The FDA has approved the first drug ever for the rare skin cancer, Merkel cell carcinoma, and updated data show an improved tumor response rate and that patients’ tumors continued to respond for at least a year.See Original Article

Continue Reading

Screen to Save Community Spotlight: UT Health San Antonio

| March 30, 2017 | 0 Comments

Screen to Save Community Spotlight: UT Health San Antonio As Screen to Save outreach activities are in progress, CRCHD will highlight education and outreach activities taking place in communities across the country. This week, CRCHD is spotlighting the work of our community health educators at the Cancer Therapy and Research Center of the University of […]

Continue Reading

Screen to Save Community Spotlight: University of Texas Health San Antonio

| March 29, 2017 | 0 Comments

Screen to Save Community Spotlight: University of Texas Health San Antonio As Screen to Save outreach activities are in progress, CRCHD will highlight education and outreach activities taking place in communities across the country. This week, CRCHD is spotlighting the work of our community health educators at the Cancer Therapy and Research Center of the […]

Continue Reading

Targeted Cancer Drug May Also Help Protect Fertility, Study Suggests

| March 27, 2017 | 0 Comments

Targeted Cancer Drug May Also Help Protect Fertility, Study Suggests Findings from a new study in mice suggest that a class of targeted cancer drugs may have another use in some younger women being treated for cancer: preserving their fertility. See Original Article

Continue Reading

RAS Pathway v3.0?

| March 24, 2017 | 0 Comments

RAS Pathway v3.0? Defining the most important elements of RAS signaling is an important objective of the NCI RAS Initiative. In a new RAS Dialogue post, advisor Frank McCormick invites community input on version 3.0 of the RAS Pathway.See Original Article Kras and Cancer Metabolism: A Conversation with Carla Martins Our cells ordinarily have two […]

Continue Reading

Colorectal Cancer Incidence Rising in Young Adults: An Interview with Drs. Philip Rosenberg and William Anderson

| March 23, 2017 | 0 Comments

Colorectal Cancer Incidence Rising in Young Adults: An Interview with Drs. Philip Rosenberg and William Anderson Drs. Philip Rosenberg and William Anderson of NCI discuss a recent study on which they were coauthors that reported an increase in colorectal cancer incidence among adults under age 50 in the United States. See Original Article

Continue Reading

Stem-Cell Based Tool May Help Measure Heart Toxicity of Cancer Drugs

| March 21, 2017 | 0 Comments

Stem-Cell Based Tool May Help Measure Heart Toxicity of Cancer Drugs Researchers have used adult stem cells to create a tool for ranking how toxic a group of cancer drugs, called tyrosine kinase inhibitors, are to human heart cells. Such a test could potentially identify toxic side effects earlier in the drug development process.See Original […]

Continue Reading

Researchers Use CRISPR Gene-Editing Tool to Help Turn Immune Cells against Tumors

| March 20, 2017 | 0 Comments

Researchers Use CRISPR Gene-Editing Tool to Help Turn Immune Cells against Tumors Using a new tool for editing genomes, known as CRISPR, researchers have genetically engineered immune cells and improved the ability of these cells to kill cancer cells in mice. See Original Article

Continue Reading

Crizotinib Approval Expanded for Advanced Lung Cancer

| March 17, 2017 | 0 Comments

Crizotinib Approval Expanded for Advanced Lung Cancer The FDA has approved uses of the targeted therapy crizotinib (Xalkori®) for patients with advanced lung cancer whose tumors have alterations in the ROS1 gene.See Original Article The Exceptional Responders Initiative: Welcoming More Cases The initiative is studying tissue, clinical, and genomic data from patients with cancer who […]

Continue Reading

FDA Approves New Use for Lenalidomide in Multiple Myeloma

| March 16, 2017 | 0 Comments

FDA Approves New Use for Lenalidomide in Multiple Myeloma The FDA has approved lenalidomide for use as a maintenance therapy in patients with multiple myeloma who have undergone an autologous stem cell transplant, to help keep the cancer from coming back.See Original Article

Continue Reading